Fisher Asset Management LLC Sells 153 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fisher Asset Management LLC decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 678 shares of the company’s stock after selling 153 shares during the period. Fisher Asset Management LLC’s holdings in IDEXX Laboratories were worth $343,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Ridgewood Investments LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $27,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new position in shares of IDEXX Laboratories in the 2nd quarter worth about $36,000. Finally, Ashton Thomas Securities LLC bought a new position in shares of IDEXX Laboratories during the 3rd quarter valued at about $37,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $421.75 on Monday. The company has a market capitalization of $34.54 billion, a price-to-earnings ratio of 40.67, a price-to-earnings-growth ratio of 3.68 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company’s 50-day moving average is $451.91 and its 200 day moving average is $477.31.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same quarter last year, the company earned $2.53 EPS. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

Analyst Ratings Changes

IDXX has been the topic of several analyst reports. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday. Piper Sandler reaffirmed a “neutral” rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. JPMorgan Chase & Co. cut their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Barclays dropped their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $552.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.